Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;57(1):2445190.
doi: 10.1080/07853890.2024.2445190. Epub 2024 Dec 23.

Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma

Affiliations

Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma

Xueling Shi et al. Ann Med. 2025 Dec.

Abstract

Objective: This study aimed to observe the dynamic changes in the expression of T lymphocytes, natural killer (NK) cells, and PD-1 in patients with first-diagnosed esophageal squamous cell carcinoma (ESCC) before and after chemoradiotherapy (CRT) and evaluate the impact of PD-1 expression in peripheral blood on the short-term outcome of patients with ESCC.

Patients and methods: Seventy-three patients with ESCC who were treated with definitive CRT were enrolled. Before and after CRT, flow cytometry was used to detect thePD-1 expression in the peripheral blood and related immune indicators. Peripheral blood from 10 healthy individuals was used as control.

Results: The percentages of CD3+ (p = 0.018), CD4+ (p < 0.001), and CD8+ T cells (p < 0.001); NK cells (p = 0.009); and the CD4+/CD8+ ratio (p < 0.001), as well as PD-1+CD3+ (p < 0.001), PD-1+CD4+ (p < 0.001), and PD-1+CD8+ (p < 0.001) T cells, before CRT significantly differed from those in the post-CRT group. The percentages of PD-1+CD8+ T cells differed significantly between the radiotherapy alone and CRT groups (p < 0.05). PD-1 expression in CD3+, CD4+, and CD8+ T cells significantly decreased in patients achieving overall response rate (all p < 0.05). Compared with those in the incomplete response group, PD-1+CD8+ T cells significantly decreased in the CR group (p < 0.05).

Conclusion: CRT aggravated immunosuppression and increased PD-1 expression in T lymphocyte subsets in patients with ESCC, possibly related to the radiation field. PD-1 expression in T lymphocyte subsets can predict short-term outcomes in patients and provide a theoretical basis for the sequential application of PD-1 immunosuppressants after radiotherapy and chemotherapy.

Keywords: NK cells; PD-1; T lymphocyte subsets; chemoradiotherapy; esophageal squamous cell carcinoma; immunotherapy.

Plain language summary

Chemoradiotherapy (CRT) reduced the overall immune function of patients with esophageal squamous cell carcinoma (ESCC), and the degree of decline was related to the irradiation area.PD-1 expression in T lymphocytes increased considerably after CRT, suggesting that the sequential application of PD-1 immunosuppressants after radiotherapy and chemotherapy can be beneficial.PD-1 expression on T lymphocytes may serve as a potential indicator for predicting the short-term outcomes of ESCC.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Flow chart of T lymphocyte subsets, PD-1, and NK cells. (a) The box on the right side represents the proportion of CD3+ cells, that is, T lymphocytes. (b) The box in Q1 represents the proportion of CD3+CD8+ cells, that is, CD8+ T cells, whereas the box in Q3 represents the proportion of CD3+CD4+ cells, that is, CD4+ T cells. (c) The circle in the box represents the proportion of CD3-CD16+CD56+ cells, that is, NK cells. (d) The circle in the box represents the proportion of CD3+CD279+ cells. The proportion represents that of PD-1 expression among the total T cells. (e) The proportion of CD4+CD279+ cells circled in the box represents that of PD-1 expression in CD4+ T cells. (f) The circle in the box represents the proportion of CD8+CD279+ cells, representing the proportion of PD-1 expression among CD8+ T cells.
Figure 2.
Figure 2.
Comparison of NK cells and T lymphocyte subsets between patients with esophageal squamous cell carcinoma and healthy controls for. T test level, *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 3.
Figure 3.
Comparison of PD-1 expression on T lymphocyte subsets between patients with esophageal squamous cell carcinoma and healthy controls. T test level, *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4.
Figure 4.
Correlation of PD-1 expression in T lymphocyte subsets. (a) PD-1 expression on CD3+ T cells vs. PD-1 expression on CD4+ T cells. (b) PD-1 expression on CD3+ T cells vs. PD-1 expression on CD8+ T cells. (c) PD-1 expression on CD4+ T cells vs. PD-1 expression on CD8+ T cells. r = Pearson correlation coefficient; p < 0.05, correlation analysis shows statistical significance.

Similar articles

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Arnold M, Abnet CC, Neale RE, et al. . Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335–349.e15. doi: 10.1053/j.gastro.2020.02.068. - DOI - PMC - PubMed
    1. Weichselbaum RR, Liang H, Deng L, et al. . Radiotherapy and immunotherapy: a beneficial liaison. Nat Rev Clin Oncol. 2017;14(6):365–379. doi: 10.1038/nrclinonc.2016.211. - DOI - PubMed
    1. Ieranò C, Righelli D, D’Alterio C, et al. . In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. J Immunother Cancer. 2022;10(3):e004032. doi: 10.1136/jitc-2021-004032. - DOI - PMC - PubMed
    1. Cooper JS, Guo MD, Herskovic A, et al. . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–1627. doi: 10.1001/jama.281.17.1623. - DOI - PubMed

MeSH terms

Substances